Clorox shares are trading lower as the market digests the company’s recent step-up in financial leverage and execution complexity following the closing of its GOJO Industries acquisition (Purell) on April 1, 2026. The deal was announced at a $2.25 billion cash purchase price and was expected to be funded primarily through debt, increasing sensitivity to interest costs and near-term integration execution.

With the transaction now closed, the narrative has shifted from “strategic fit” to “delivery risk,” including how quickly Clorox can integrate GOJO operations, protect margins, and translate cross-channel ambitions (consumer plus institutional hygiene) into measurable revenue and cash flow. Traders are also watching whether incremental financing and working-capital needs crowd out flexibility while Clorox continues to manage operational initiatives like its ERP transition.

Selling pressure is being reinforced by a recent cluster of analyst price-target reductions in early April, including a Wells Fargo target cut to $110 and a UBS reduction to $110, keeping attention on a more cautious near-term setup for staples names with company-specific execution risks. Those updates have contributed to a more defensive tone around CLX as the stock trades near the low-$100s.

Key signposts include any updated commentary on GOJO integration milestones, synergy timing, and the pace of institutional-channel expansion for Purell under the new Clorox Purell business unit. Investors will also watch for leverage metrics, interest expense trajectory, and whether management maintains or adjusts FY2026 expectations as acquisition-related costs and operational changes flow through results.